Equities

Structure Therapeutics Inc

GPCR:NMQ

Structure Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)33.00
  • Today's Change2.90 / 9.63%
  • Shares traded836.84k
  • 1 Year change-35.76%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 18:53 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy3
Outperform8
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 10 analysts offering 12 month price targets for Structure Therapeutics Inc (ADR) have a median target of 89.00, with a high estimate of 118.00 and a low estimate of 65.00. The median estimate represents a 195.68% increase from the last price of 30.10.
High292.0%118.00
Med195.7%89.00
Low115.9%65.00

Earnings history & estimates in USD

On Nov 13, 2024, Structure Therapeutics Inc (ADR) reported 3rd quarter 2024 losses of -0.20 per share.
The next earnings announcement is expected on Mar 06, 2025.
Average growth rate+14.73%
Structure Therapeutics Inc (ADR) reported annual 2023 losses of -2.43 per share on Mar 08, 2024.
Average growth rate+55.90%
More ▼

Revenue history & estimates in USD

Structure Therapeutics Inc (ADR) did not report revenues for the 3rd quarter 2024. However, during the 3rd quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
Structure Therapeutics Inc (ADR) did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.